Atsuhiro Kawaguchi

Amiselimod, a novel sphingosine 1‐phosphate receptor‐1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk

Kunio Sugahara, Yasuhiro Maeda, Kyoko Shimano et al. · British Journal of Pharmacology · 2016 · 86 citations · Full text

Medicine, Cardiology, Pharmacology +17

Different effects of St John's Wort on the pharmacokinetics of simvastatin and pravastatin

Koichi Sugimoto, Masami Ohmori, Shuichi Tsuruoka et al. · Clinical Pharmacology & Therapeutics · 2001 · 75 citations

Medicine, Pharmacokinetics, Pharmacology +12

Bioactive Constituents of Chinese Natural Medicines. VI. Moutan Cortex. (2): Structures and Radical Scavenging Effects of Suffruticosides A, B, C, D, and E and Galloyl-oxypaeoniflorin

Hisashi Matsuda, Toshio Ohta, Atsuhiro Kawaguchi et al. · Chemical and Pharmaceutical Bulletin · 2001 · 69 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +13

Tolerability, pharmacokinetics and pharmacodynamics of <scp>TA</scp>‐8995, a selective cholesteryl ester transfer protein (<scp>CETP</scp>) inhibitor, in healthy subjects

J. Ford, Matt Lawson, D. E. Fowler et al. · British Journal of Clinical Pharmacology · 2014 · 58 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +9

Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans

Yoshinobu Nakamaru, Yoshiharu Hayashi, Ruriko Ikegawa et al. · Xenobiotica · 2013 · 56 citations

Medicine, Pharmacokinetics, Pharmacology +12